Funding Briefs

The Alfred P.: Sloan Foundation in New York City may place even more emphasis on science and technology once its new president has settled into his job. Last month Ralph E. Gomory, a mathematician and former senior vice president for science and technology at IBM, took charge of the 55-year-old organization. Although neither Gomory nor the foundation will let on what new emphases might be in the works until he has been there a few more months, Gomory has made known his keen interest in problems

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The Alfred P.: Sloan Foundation in New York City may place even more emphasis on science and technology once its new president has settled into his job. Last month Ralph E. Gomory, a mathematician and former senior vice president for science and technology at IBM, took charge of the 55-year-old organization. Although neither Gomory nor the foundation will let on what new emphases might be in the works until he has been there a few more months, Gomory has made known his keen interest in problems of industrial competitiveness.

With more than $550 million in assets and $20 million in annual grants, Sloan ranks among the 25 largest foundations. Nearly 90% of its grants are for science fellowships and programs, most notably about 100 research fellowships to young scientists. Its Science and Society division sponsors a program that encourages and finances the writing of books both about and by prominent ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies